Photo courtesy of VelosBio.
VelosBio’s pipeline seeks to produce novel targeted therapies across a broad range of cancers.

Photo courtesy of VelosBio. VelosBio’s pipeline seeks to produce novel targeted therapies across a broad range of cancers.

San Diego-based VelosBio, a company which is developing an antibody-drug conjugate that goes after a target of growing interest, has raised $137 million from venture capitalists...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99